215 related articles for article (PubMed ID: 27091655)
1. Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.
Kadra G; Stewart R; Shetty H; Downs J; MacCabe JH; Taylor D; Hayes RD
Schizophr Res; 2016 Jul; 174(1-3):106-112. PubMed ID: 27091655
[TBL] [Abstract][Full Text] [Related]
2. Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality.
Kadra G; Stewart R; Shetty H; MacCabe JH; Chang CK; Taylor D; Hayes RD
Acta Psychiatr Scand; 2018 Aug; 138(2):123-132. PubMed ID: 29845597
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic polypharmacy prescribing and risk of hospital readmission.
Kadra G; Stewart R; Shetty H; MacCabe JH; Chang CK; Kesserwani J; Taylor D; Hayes RD
Psychopharmacology (Berl); 2018 Jan; 235(1):281-289. PubMed ID: 29080904
[TBL] [Abstract][Full Text] [Related]
5. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850
[TBL] [Abstract][Full Text] [Related]
6. Social and clinical descriptors of antipsychotic prescription.
Piccinni C; Piazza A; Poluzzi E; Tarricone I; Koci A; Berardi D; Fioritti A; de Ponti F
Int J Psychiatry Med; 2015; 49(1):45-62. PubMed ID: 25838320
[TBL] [Abstract][Full Text] [Related]
7. Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.
Kadra G; Stewart R; Shetty H; Jackson RG; Greenwood MA; Roberts A; Chang CK; MacCabe JH; Hayes RD
BMC Psychiatry; 2015 Jul; 15():166. PubMed ID: 26198696
[TBL] [Abstract][Full Text] [Related]
8. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
9. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.
John AP; Gee T; Alexander S; Ramankutty P; Dragovic M
Australas Psychiatry; 2014 Dec; 22(6):546-50. PubMed ID: 25147317
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong.
Lung SLM; Lee HME; Chen YHE; Chan KWS; Chang WC; Hui LMC
Asian J Psychiatr; 2018 Mar; 33():113-120. PubMed ID: 29574303
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.
Armstrong KS; Temmingh H
Braz J Psychiatry; 2017; 39(4):293-301. PubMed ID: 28177063
[TBL] [Abstract][Full Text] [Related]
15. Long-term combination antipsychotic treatment in VA patients with schizophrenia.
Kreyenbuhl J; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Schizophr Res; 2006 May; 84(1):90-9. PubMed ID: 16631354
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
18. Delays before Diagnosis and Initiation of Treatment in Patients Presenting to Mental Health Services with Bipolar Disorder.
Patel R; Shetty H; Jackson R; Broadbent M; Stewart R; Boydell J; McGuire P; Taylor M
PLoS One; 2015; 10(5):e0126530. PubMed ID: 25992560
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital.
Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M
CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766
[TBL] [Abstract][Full Text] [Related]
20. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
